Close Menu

NEW YORK (GenomeWeb) – Cytox said today that it has raised £2.6 million ($3.3 million) in new financing. The British genetics company will use the proceeds to support the roll out of its Alzheimer's disease testing service.

GM&C Life Sciences Fund — a Manchester, UK-based seed and early stage venture capital fund managed by Catapult Ventures — led the round as a new investor. Existing investors Perivoli Innovations, the Rainbow Seed Fund, the University of Oxford, and other private investors also contributed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.